13 results
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
executives at Immunocore are appropriately compensated and incentivised to deliver growth to shareholders in a long- term and sustainable manner … to deliver sustainable long-term growth and shareholder value.
While the Committee references US market practice as the primary benchmark for both
424B7
IMCR
Immunocore Holdings plc
5 Apr 24
Prospectus with selling stockholder info
4:34pm
of reaching patients in additional indications and territories;
our ability to build a sustainable pipeline of new product candidates, including … timing of reaching patients in additional indications and territories;
our ability to build a sustainable pipeline of new product candidates, including
PRE 14A
IMCR
Immunocore Holdings plc
2 Apr 24
Preliminary proxy
4:45pm
executives at Immunocore are appropriately compensated and incentivised to deliver growth to shareholders in a long- term and sustainable manner … sustainable long-term growth and shareholder value.
While the Committee references US market practice as the primary benchmark for both Executive
S-3ASR
IMCR
Immunocore Holdings plc
20 Mar 24
Automatic shelf registration
8:51pm
timing of reaching patients in additional indications and territories;
our ability to build a sustainable pipeline of new product candidates … for mUM, including expanding into and the related timing of reaching patients in additional indications and territories;
our ability to build a sustainable
8-K
EX-99.2
IMCR
Immunocore Holdings plc
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
for sustainable growth David Berman, Head of R&D Delivering on our promise Bahija Jallal, CEO Q&A Session 3 4Q23 & FY23 financial results Brian Di Donato, CFO … Areas NEW autoimmune candidates: Type 1 diabetes candidate Universal candidate for dermatology Innovating for sustainable growth Large patient
8-K
EX-99.1
v51kbgp19 r93p
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
10-K
6fibailu cin
28 Feb 24
Annual report
7:33am
8-K
EX-99.2
z0ajo2yldpmz zgj
29 Jan 24
Immunocore Announces Proposed Convertible Senior Notes Offering
5:06pm
424B7
vzxnevwwbla5
30 Sep 22
Prospectus with selling stockholder info
4:15pm
424B5
bkugyd
9 Sep 22
Prospectus supplement for primary offering
4:23pm
424B7
osk3g
5 May 22
Prospectus with selling stockholder info
12:00am
F-3ASR
bqvdkt wr5k
4 Apr 22
Automatic shelf registration (foreign)
4:08pm
- Prev
- 1
- Next